Merck 2010 Annual Report Download - page 51
Download and view the complete annual report
Please find page 51 of the 2010 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41 -
42 -
43 -
44 -
45 -
46 -
47 -
48 -
49 -
50 -
51 -
52 -
53 -
54 -
55 -
56 -
57 -
58 -
59 -
60 -
61 -
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
-
201
-
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
-
216
-
217
-
218
-
219
-
220
-
221
-
222
-
223
 |
 |
– Oncology: Erbitux ® (solid tumors)
– Neurodegenerative Diseases: Rebif ®, Movectro ® (multiple sclerosis)
– Fertility: Gonal-f ®, Pergoveris™, Luveris ®, Ovitrelle ®, Crinone ®, Cetrotide ® (infertility treatment)
– Endocrinology: Saizen ® (growth hormone disorders), Serostim ® (HIV-associated wasting),
Kuvan ® (metabolic disorder hyperphenylalaninemia), Egrifta™ (HIV-associated lipodystrophy)
– CardioMetabolic Care: Concor ® franchise (cardiovascular diseases), Glucophage ® franchise
(type 2 diabetes), Euthyrox ® (thyroid disorders)
– Sales of Erbitux ® rise by 18% to EUR 820 million, Rebif ® sales increase by 8.6% to
EUR 1,668 million
– Russian and Australian regulatory authorities approve cladribine tablets as the world’s first
oral disease-modifying treatment for multiple sclerosis (brand name: Movectro ®)
– The Committee for Medicinal Products for Human Use of the EMA adopts a final negative
opinion regarding the marketing authorization application for cladribine tablets in January
2011. In the United States, the FDA accepts the application for review; FDA feedback on the
application is expected by the end of February 2011
– The Japanese drug regulatory authorities approve extended usage for Erbitux ® in combination
with chemotherapy for first-line treatment of metastatic colorectal cancer (KRAS wild-type
tumors)
– Following a suspected unexpected serious adverse reaction we temporarily suspended all
studies with the cancer immunotherapy Stimuvax ® in March. Phase III trials resumed in non-
small cell lung cancer in June
– Egrifta™ approved in the United States to reduce excess abdominal fat in HIV patients with
lipodystrophy
Merck Serono is the largest division of Merck. It markets innovative pre-
scrip tion drugs of chemical and biotechnological origin. The division offers
its leading brands in around 150 countries. Merck Serono focuses on highly
specialized therapeutic areas such as Neurodegenerative Diseases, Oncology,
Fertility, Endocrinology and Rheumatology.
Company 47Management Report Corporate governance Consolidated Financial Statements More information
Merck Serono